Navigation Links
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Date:1/8/2009

CRANBURY, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr. Barer brings over 20 years of management experience and a reputation as a trusted and respected leader who has helped transform Celgene into one of the world's preeminent biopharmaceutical companies.

John F. Crowley, President and CEO of Amicus Therapeutics stated, "2009 will be an important year for the Company as we leverage our chaperone technology and continue to advance our three lead drug candidates for Fabry, Gaucher and Pompe diseases. We look forward to Dr. Barer's leadership and guidance as Amicus continues along the path of development and commercialization for new, oral treatments for a range of human genetic diseases. We welcome him to our Board."

Separately, Amicus announced today that Gregory M. Weinhoff has chosen to resign from the Board of Directors effective January 7, 2009.

About Sol. J. Barer, Ph.D.

Dr. Barer has been Chief Executive Officer of Celgene Corporation since May 1, 2006, and Chairman since January 1, 2007. He was appointed President of Celgene in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors. He previously served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from 1991 to 1994, and the Vice President, Technology, from 1987 to 1991. Dr. Barer is on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves on the Board of Trustees of the Biotechnology Council of New Jersey and is on the Board of the Brooklyn College'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
2. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
3. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
4. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
5. Amicus Therapeutics Opens Research Facility in San Diego
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
8. Amicus Therapeutics Announces First Quarter 2008 Financial Results
9. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... ... prominent, board certified anesthesiologist Barry Friedberg, MD. “Is the ASA not as smart as a ... (PRWEB) March ... be in the relentless pursuit of patient safety ., , , , ,Yet no ...
... ... ... ... ...
... ... Users, Technology-agnostic Data-mining Platform Integrates a Variety of Data Streams into One Easy-to-use Analysis ... (PRWEB) ... discovery and life science research, today announced Genedata Analyst™, an integrated statistical and data ...
Cached Biology Technology:American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 2American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 2Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 4Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 5Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 6Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 2Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 3Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 4Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 5
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... ... of four British engineers has returned to the UK after completing a gruelling ... to put in place equipment and supplies for an ambitious project later this ... has successfully paved the way to explore an ancient lake buried beneath 3 ...
... -- Just like people, some proteins have characteristic ways of ... to describe. But now scientists have discovered the unique "drunken ... the function of every cell in the body and whose ... Gehrig,s disease and Parkinson,s disease. The research, which ...
... CAMBRIDGE, Mass. (January 13, 2012) The blood-brain barrier is ... viruses and bacteria and isolating the brain,s specific hormonal and ... In addition to nerve cells, the brain contains ... fruit fly, the blood-brain boundary is made by glia joined ...
Cached Biology News:Engineering team completes ambitious Antarctic expedition in the 'deep-field' 2Engineering team completes ambitious Antarctic expedition in the 'deep-field' 3Walk this way: Scientists and MBL physiology students describe how a motor protein 'steps out' 2Brain glia cells increase their DNA content to preserve vital blood-brain barrier 2
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... siRNA --- a cocktail of 3 siRNAs ... interestis our most popular product. The siTrio ... knockdown of your target gene when used ... transfection and confirmation of optimal transfection with ...
... kit #27295 has improved stability and convenience from ... not only has overcome this problem but also ... have changed the formulation of HRP conjugated antibody ... By this change, the stability of the conjugate ...
... IDS EIA kit is a complete assay ... D (1,25D) in human serum or plasma. ... system found in the IDS 1,25D RIA ... assay comes with ready to use reagents, ...
Biology Products: